This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, is pleased to announce that the first human implantation of the company’s map3™ Cellular Allogeneic Bone Graft implant was completed last week.
Dr. Franco E. Vigna, M.D., M.P.H., a board-certified orthopedic surgeon with Spine Surgery of Buffalo Niagara and a fellow with American Academy of Orthopaedic Surgeons, performed the first implantation during a spinal surgery in New York. He used the implant’s chips allograft configuration, one of two configurations that will be available once the implant launches.
“I am excited to have map3 as an option for my patients because of its specific osteogenic and angiogenic properties,” said Vigna, who has been honored as one of the top American orthopedists in spinal care, according to the Consumers’ Research Council of America, 2009. “The future of spine surgery is biologics. We can place the best metal implants but if the bony fusion does not take place, those implants will loosen and the fusion will fail. Having top quality natural biologics along with excellent metal implants gives physicians and patients the best of both worlds.”
Map3 cellular allogeneic bone graft is a natural and safe alternative to autograft. Map3 provides a streamlined approach to bone grafting and supplies the three elements necessary for bone repair—osteogenesis, osteoinduction and osteoconduction—in a single allograft. Map3 incorporates multipotent adult progenitor cell-based (MAPC™-based) technology with stem cells isolated from the same donor as the other bone material. The MAPC technology, licensed from Athersys, Inc. for this orthopedic application, represents a distinctive type of stem cell with recognized angiogenic and immuno-modulatory properties. Once launched, map3 will be available in multiple configurations and sizes, providing bone grafting options for various bone repair, reconstruction and fusion procedures.
“We are thrilled to reach this milestone for map3,” said Brian K. Hutchison, RTI president and CEO. “The MAPC-based technology offers the greatest potential to create high quality, innovative implants for our surgeons and their patients and will greatly enhance our company’s orthobiologics offerings. We anticipate a market release of the implant later this year.”